Ramaswamy Govindan, MD, of Washington University, summarizes three important papers: ROVA-T in relapsed and refractory small cell lung cancer, genomic characterization of large-cell neuroendocrine tumors, and the ECOG study on bevacizumab following chemotherapy for resected non–small cell lung cancer.
Nagashree Seetharamu, MD, of the North Shore LIJ Health System, discusses serum AGA-signatures that may provide a minimally invasive test for early detection of lung cancer risk (Abstract P3.04-085).
Tony Mok, MD, of The Chinese University of Hong Kong, and Fred R. Hirsch, MD, PhD, of University of Colorado Health Science Center discuss the highlights of the featured plenary session, which included the conference’s top four abstracts (Abstract PLEN04).
William D. Travis, MD, of Memorial Sloan Kettering Cancer Center, gives an update on the WHO classification, which is crucial for optimal personalized treatment of lung cancer patients (Abstract PLEN02.01).
Fred R. Hirsch, MD, PhD, of the University of Colorado Health Science Center, and Paul A. Bunn, Jr, MD, of the University of Colorado Cancer Center, give their views on the goals and important presentations of the 2015 World Conference on Lung Cancer.
Christine D. Berg, MD, of Johns Hopkins Medicine, discusses how increased insurance coverage should dramatically increase lung cancer screening. If done correctly—which will be a challenge—screening will help improve the prognosis of patients with lung cancer (Abstract PLEN 01.01).
